$CYT News

Last published 3mo ago

3mo agoCYT CYT1Syensqo - Q2 2026 Results - Analyst Call - CYTEC INDUSTRIES INCEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to the SciEnSchool Second Quarter 2026 Results Analyst Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a qu
1y agoCYT CYT1Syensqo - Q3 2025 Results - Analyst Call - CYTEC INDUSTRIES INCEarnings Call TranscriptsThank you for standing by and welcome to ScienceCo third quarter 2025 earnings call. My name is Rochelle and I will be conference operator today. All lines have been placed on mute to prevent any background noise. After
2y agoCYTCyteir Announces Timeline for Voluntarily Delisting from NasdaqBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today announced that it has formally notified The Nasdaq Stock Market ("Nasdaq") of its intent to delist the Company's common stock from the Nasdaq Global Select Market.
2y agoBCYC CYTBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsBusiness WireCatalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer now active and
3y agoCYTOngoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety ProfileBusiness Wire- CYT-0851 demonstrated activity in combination with capecitabine in heavily pretreated platinum-refractory or -resistant ovarian cancer patients with a generally well tolerated safety profile - Overall disease
3y agoCYTCyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and DissolutionBusiness WireCyteir Therapeutics, Inc. ("Cyteir" or the "Company") (NASDAQ:CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that Cyteir's Board
3y agoCYTPreliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety ProfileBusiness Wire- CYT-0851 has demonstrated early activity in combination with capecitabine or gemcitabine in advanced solid tumors and a generally well tolerated safety profile in a heavily pretreated population of patients -
3y agoCYTCyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational HighlightsBusiness Wire- Enrollment continuing in trials with CYT-0851 in combination with capecitabine or gemcitabine with data expected in mid-2023 - Ended first quarter of 2023 with approximately $137.2 million in cash Cyteir
3y agoCYTCyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsBusiness WireInitial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147
3y agoCYTCyteir Therapeutics Promotes David Gaiero to Chief Financial OfficerBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at
3y agoCYTCyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash RunwayBusiness Wire- Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together
4y agoCYTCyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational HighlightsBusiness Wire- Initial data from CYT-0851 monotherapy solid tumor Phase 2 cohorts are now expected in first quarter of 2023 - Initial data from Phase 1 combination solid tumor cohorts are expected in first half of 2023 - Ended
4y agoCYTCyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR SymposiumBusiness Wire- Poster details the research into CYT-0851 mechanism of action and identification as an inhibitor of monocarboxylate transporter activity Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the
4y agoCYTCyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, wil
4y agoCYTCyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational HighlightsBusiness Wire- Sharpening focus on the pipeline extends cash runway into second half of 2024; Ended quarter with approximately $166 million in cash - IND submission for CYT-1853 postponed to focus on CYT-0851 and preclinical pipeline Cyteir Therapeutics, Inc.
4y agoCYTCyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual ConferenceBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, wil
4y agoCYTCYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic MalignanciesBusiness Wire- CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients - Durable responses seen in both solid tumors and hematologic malignancies in the dose escalation with a
4y agoCYTCyteir Therapeutics to Participate in the 2022 Jefferies Healthcare ConferenceBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participa
4y agoCYTCyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational HighlightsBusiness Wire- Safety and efficacy data expected for second half 2022 for CYT-0851 monotherapy and combination studies - CYT-0851 mechanism of action identified as inhibition of monocarboxylate transporter (MCT) activity; new findings potentially expand future op
4y agoCYTCyteir Therapeutics to Participate in the 2022 Bank of America Healthcare ConferenceBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Andrew Gengos, Chief Business Officer and Judd Englert, MD, PhD, Senior Vi
4y agoCYTCyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and QualityBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Krisztina Nemenyi, PhD, RAC, to its leadership team as
4y agoCYTCyteir Therapeutics Names Adam Veness General CounselBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced today that Adam Veness, Esq. has joined Cyteir as General Counsel effective tod
4y agoCYTCyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022Business WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a virtual R&D Day on April 26, 2022 starting at 8:30 a.m. ET. Cyteir's manageme
4y agoCYTCyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational HighlightsBusiness Wire- Continue to enroll in monotherapy and combination studies with CYT-0851 with potential for interim safety and efficacy data in second half 2022 - Progress achieved in key clinical milestones described in the 2021 IPO: Advanced CYT-0851 monotherapy
4y agoCYTCyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022Business WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p
4y agoCYTCyteir Therapeutics Announces the Appointment of Stephen Sands to Board of DirectorsBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Stephen Sands to its Board of Directors, to serve as a
4y agoCYTCyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851Business WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the first patient has been dosed in a Phase 2 expansion cohort study
4y agoCYTCyteir Therapeutics Announces the Appointment of John F. Thero to Board of DirectorsBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of John F. Thero to its board of directors. Mr. Thero wil
4y agoCYTCyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851Business WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the first patient has been dosed in a Phase 1 trial evaluating CYT-0
4y agoCYTCyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare ConferenceBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD, will prese
4y agoCYTCyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of DirectorsBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Dr. Jeffrey S. Humphrey, MD, Chief Medical Officer of
5y agoCYTCyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business HighlightsBusiness Wire- Phase 2 dose identified for CYT-0851 and initiation activities ongoing for Phase 2 monotherapy expansion study and Phase 1/2 combination studies - Ended quarter with approximately $200 million in cash to continue to advance our pipeline and to fund
5y agoCYTCyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare ConferenceBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will partic
5y agoCYTCyteir Therapeutics Selected to Join Russell 2000® IndexBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was added as a member of the U.S. small-cap Russell 2000® Index, effective after the US m
5y agoALXO CYT GMTXLightstone Ventures Raises $375 Million FundPR NewswireMENLO PARK, Calif. and BOSTON, Sept. 14, 2021 /PRNewswire/ -- Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and
5y agoCYTCyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare ConferenceBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will partic
5y agoCYTCyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business HighlightsBusiness Wire- IPO raised an aggregate of approximately $149.1 million in gross proceeds - Strong cash position of $198.6 million to be used to deliver expected key value-creating milestones and fund operations through 2023 - Lead program, CYT-0851, advancing
5y agoCYTCyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare ConferenceBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will partic
5y agoCYTCyteir Therapeutics Announces Closing of Initial Public OfferingBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its com
5y agoCYTCyteir Therapeutics Announces Pricing of Initial Public OfferingBusiness WireCyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the pricing of its initial public offering of 7,400,000 shares of its com
11y agoFLR CYTFluor Awarded Cytec’s UK Adhesives Expansion ProjectBusiness WireFARNBOROUGH, U.K.--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) announced today that Fluor Limited, its UK operation, was selected by Cytec Industries Inc. (NYSE:CYT) for the engineering, procurement and construction management (EPCM) of the expansion of its high-performance adhesives manufacturing facility in Wrexham, North Wales. Fluor booked the undisclosed value of the contract in the compan ...
11y agoCYTLaw Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Cytec Industries, Inc. StockholdersBusiness WireNEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of Cytec Industries, Inc. (“Cytec” or the “Company”) (NYSE:CYT) concerning the proposed acquisition of the Company by Solvay SA. Pursuant to the terms of the agreement, Cytec stockholders will receive $75.25 in cash for each share of Cytec common stock they own, in a transaction valued a ...
14y agoCYTCOMAC Selects Cytec for C919Business WireWOODLAND PARK, N.J.--(BUSINESS WIRE)--Cytec Industries Inc. (NYSE:CYT) announced today that its Engineered Materials business has been awarded a long-term agreement to supply certain high-performance, structural composite and adhesive materials for the Commercial Aircraft Corporation of China, Ltd. (COMAC) C919 commercial aircraft. The contract with Shanghai Aircraft Manufacturing Co., Ltd. (SAMC) ...
14y agoCYTCytec Honored with Achievement Award for Addressing F-35 Cost ReductionsBusiness WireWOODLAND PARK, N.J.--(BUSINESS WIRE)--Cytec Industries Inc. (NYSE:CYT) today announced that its Engineered Materials business was honored as part of an aerospace industry team receiving the 2011 Defense Manufacturing Technology (ManTech) Achievement Award from the US Department of Defense (DoD). The award was presented at the recent Defense Manufacturing Conference in Anaheim, California and recog ...
14y agoCYTCytec Showcases Applications Engineering Expertise at Carbon Fiber 2011 ConferenceBusiness WireWOODLAND PARK, N.J.--(BUSINESS WIRE)--Cytec Industries Inc. (NYSE:CYT) today announced Carmelo Lo Faro, Vice President of Technology, Engineered Materials will be speaking at CompositesWorld's Carbon Fiber 2011 conference. The conference is being held December 5, 6 and 7 at the Washington Marriott in Washington, DC.
15y agoCYTCytec Presents Advances in Composite Technology at International Conference “Supply on the Wings”Business WireWOODLAND PARK, N.J.--(BUSINESS WIRE)--Cytec Industries Inc. (NYSE:CYT) today announced Chris Pederson, Vice President Aerospace, Engineered Materials will be a keynote speaker at the 6th International Conference “Supply on the Wings.” The conference is being held November 2, 3 and 4 at Exhibition Centre, Frankfurt / Main, Germany in conjunction with AIRTEC International Aerospace Supply Fair.
15y agoCYTCytec Materials Take Flight On 787Business WireWOODLAND PARK, N.J.--(BUSINESS WIRE)--Cytec Industries’ (NYSE:CYT) Engineered Materials division congratulates The Boeing Company on the 787 Dreamliner’s entry into service with launch customer ANA. This historic event marks the inauguration of the first large commercial transport with significant use of composite materials for wing and fuselage structures. Cytec Engineered Materials is proud to s ...
15y agoCYTCytec Presents Recent Composite Developments at Innovative International Composites SummitBusiness WireWOODLAND PARK, N.J.--(BUSINESS WIRE)--Cytec Industries Inc. (NYSE:CYT) today announced Carmelo Lo Faro, Vice President of Technology, Engineered Materials will be chairing a session and speaking at the Innovative International Composites Summit. The Summit is being held October 18, 19 and 20 at SUNTEC International Convention and Exhibition Centre in Singapore as part of JEC Asia 2011.
15y agoCYT LMTLockheed Martin Extends Cytec ContractBusiness WireWOODLAND PARK, N.J.--(BUSINESS WIRE)--Cytec Industries Inc. (NYSE:CYT) announced today that its Engineered Materials business had signed a contract extension, covering the period from 2016 to 2020, with Lockheed Martin (NYSE: LMT) for the supply of high-performance, structural composite and adhesive materials used in the manufacture of the multinational F-35 Lightning II Program or Joint Strike Fi ...
15y agoCYTCytec Declares Quarterly DividendBusiness WireWOODLAND PARK, N.J.--(BUSINESS WIRE)--Cytec Industries Inc. (NYSE:CYT) announced today that the company’s Board of Directors declared a regular quarterly cash dividend of $0.125 per share on the common stock of the company, payable on May 25, 2011 to shareholders of record as of May 10, 2011.